Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab - Genentech/Roche

X
Drug Profile

Bevacizumab - Genentech/Roche

Alternative Names: Anti-VEGF - Roche; Anti-VEGF Humanized Monoclonal Antibody - Roche; Anti-VEGF rhuMAb - Roche; Avastin; RG-435; rhuMAb-VEGF; RO-4876646

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Hackensack University Medical Center
  • Developer All Ireland Cooperative Oncology Research Group; ARCAGY/GINECO Group; Austrian Breast & Colorectal Cancer Study Group; Bayer; Beth Israel Deaconess Medical Center; Breast Cancer Research Foundation; Brigham and Women's Hospital; Bristol-Myers Squibb; Cancer and Leukemia Group B; Cancer Research UK; Chugai Pharmaceutical; Cincinnati Children's Hospital Medical Center; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Indiana University School of Medicine; Japan Breast Cancer Research Group; M. D. Anderson Cancer Center; Massachusetts General Hospital; Melanoma Research Foundation Breakthrough Consortium; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); National Comprehensive Cancer Network; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Norwegian Radium Hospital; NSABP Foundation; Ohio State University Medical Center; Peter MacCallum Cancer Centre; Roche; Royal Marsden NHS Foundation Trust; Sanofi; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; Servier; South Eastern European Research Oncology Group; Spanish Cooperative Group for Digestive Tumour Therapy; Spanish Lung Cancer Group; Stanford University School of Medicine; SWOG; The Catalan Institute of Oncology; UNICANCER; University College London; University of Alabama at Birmingham; University of Arkansas System; University of California, Davis; University of Iowa; University of Oklahoma; University of Tennessee; University of Texas M. D. Anderson Cancer Center; US Oncology Research; West German Study Group; Xijing Hospital
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peritoneal cancer; Glioma; Cervical cancer; Ovarian cancer; Fallopian tube cancer; Renal cell carcinoma; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Glioma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Registered Fallopian tube cancer; Peritoneal cancer
  • Phase III Head and neck cancer; Malignant-mesothelioma; Small cell lung cancer
  • Phase II/III Malignant melanoma
  • Phase II Biliary cancer; Brain metastases; Endometrial cancer; Ewing's sarcoma; Gastric cancer; Gynaecological cancer; Hodgkin's disease; Intestinal cancer; Liver metastases; Meningioma; Multiple myeloma; Neuroblastoma; Neurofibromatosis 1; Rectal cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Phase I/II Neoplastic meningitis; Sarcoma
  • Suspended Carcinoid tumour
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Eye disorders; Gastrointestinal stromal tumours; Oesophageal cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 26 Apr 2024 Hoffmann-La Roche completes a phase IIIb ATHECA trial for Liver cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) (IV) in Spain (IV) (NCT04732286)
  • 05 Apr 2024 Efficacy data from the phase III IMpower151 trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 13 Feb 2024 AstraZeneca initiates enrolment in the phase-II EMERALD-Y90 trial for Liver cancer (Combination therapy, Inoperable/Unresectable, First-line therapy) in USA (IV) (NCT06040099)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top